| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.13% | 33.92% | 22.24% | 15.46% | 7.42% | -26.11% | -118.07% | -304.68% |
| Operating Margin | -55.83% | -99.72% | -130.22% | -139.56% | -127.21% | -235.24% | -466.29% | -2320.03% |
| EBITDA Margin | -52.20% | -94.69% | -125.76% | -135.08% | -122.18% | -228.91% | -456.45% | -2266.77% |
| Net Margin | -68.34% | -112.57% | -132.54% | -141.24% | -128.59% | -243.30% | -452.97% | -2480.32% |
| Current Ratio | 6.67 | 5.69 | 5.26 | 7.19 | 7.93 | 9.43 | 3.20 | — |
| Quick Ratio | 5.40 | 4.38 | 4.37 | 6.20 | 7.17 | 8.93 | 3.01 | — |
| Debt / Equity | 0.76 | 7.36 | 1.06 | 0.41 | 0.08 | 0.10 | -0.08 | — |
| ROE | -64.32% | -477.18% | -140.62% | -66.24% | -35.27% | -36.97% | 18.35% | — |
| ROA | -30.87% | -46.40% | -55.07% | -40.73% | -28.47% | -30.09% | -77.29% | — |
| Asset Turnover | 0.45 | 0.41 | 0.42 | 0.29 | 0.22 | 0.12 | 0.17 | — |
| Book Value / Share | 8346.07 | 516.24 | 2478.14 | 5107.66 | 8205.51 | 20088.58 | -433.78 | — |
Outset Medical Inc. is a pioneering company in the medical technology field, primarily focusing on the development and commercialization of innovative dialysis solutions. Its flagship product, the Tablo Hemodialysis System, is designed to simplify dialysis treatments, whether in medical facilities or at home. The system integrates water purification with dialysate production, offering a seamless, all-in-one dialysis solution. This transformative approach aims to make dialysis more accessible and user-friendly for patients and healthcare providers. Outset Medical's advancements in the dialysis sector are significant, as they strive to redefine treatment standards and improve patient quality of life. Headquartered in the United States, Outset Medical continues to impact the healthcare industry by addressing the growing demand for efficient and scalable renal care solutions.